Icon, like most of the world's largest CROs, is investing in high-tech adaptive trial monitoring, and the company's latest offering allows investigators to comb through huge dumps of lab data in real time, tracking trial trends as they happen.
WuXi PharmaTech, China's largest CRO, banked another strong revenue quarter thanks to escalating demand for clinical trials in its home country, and now the company is raising its annual profit expectations by about 7.6%.
Two months after merging with ReSearch Pharmaceutical Services to form the world's fourth-largest CRO, PRA is back on the buyer's block, snatching up the early-stage-focused CRI Lifetree.
Patient-recruitment specialist Synexus has opened an administrative center in Wroclaw, Poland, designed to oversee its expansion throughout Eastern Europe.
Cancer drug developer Cel-Sci ($CVM) wants at least $50 million in damages in from ex-CRO partner inVentiv Health, claiming breach of contract and fraud.
Quintiles declined to divulge financials when it signed up to buy Novella Clinical in August, but a regulatory filing reveals that the world's largest CRO spent $146.5 million upfront for the contractor, with more money on the line tied to milestones.
Deal-happy CMO Capsugel hasn't forgotten about its latest acquiree, planning to invest $20 million in Bend Research's spray-dried dispersion technology just a month after closing the buyout deal.
With three year's of back-and-forth with the FDA under its belt, contract drug developer AMRI has finally closed the book on an agency warning letter tied to its Burlington, MA, plant, ending a protracted saga that has cost the company millions.
As regulators the world over clamp down on biologics development, Covance has struck up a partnership with Pathoquest to offer next-generation sequencing-based tests for biotherapeutics.
Irish CRO Venn Life Sciences has agreed to trade nearly $1 million of stock for Germany's CRM Clinical Trials, a move that will stretch its reach into one of Europe's largest research markets.
Despite ongoing slowness in the market for early-stage research, preclinical specialist Charles River Laboratories boosted its revenue and income in the third quarter, a credit to its continued cost cuts and gains in market share, the company said.
Global CRO Covance rode a spike in demand for its late-stage services to a solid third quarter, increasing its revenue guidance and counting on a bump in business to light the way for Q4.
Quintiles, the world's largest CRO, is raising its annual profit projection as new partnerships and soaring income made up for flat revenue in the third quarter.
Outsourcing magnate inVentiv Health is padding its patient-adherence offerings, snapping up Catalina Health and merging the company with its Adheris subsidiary, a move it said creates the nation's largest provider of such services.
CRO giant Parexel International posted quarterly gains in sales and net income, but a dip in new business spooked investors, dropping the company's shares as much as 17% on Wednesday.
Dutch CMO PharmaCell has inked a deal with the struggling Dendreon to manufacture its prostate cancer drug Provenge in Europe.
CRO giant inVentiv Health has opened a one-stop shop in the London suburbs, consolidating three of its U.K. operations into one all-encompassing office to better meet European demand.
CRO Novum has opened its latest hub for clinical trials, expanding into Fargo, ND, in an effort to grow the company's footprint and diversify its offerings.
Research outfit SRI International is bolstering its CRO division, spending millions to stretch its capabilities and lure more drug development clients to its Virginia labs.
CRO giant Icon is riding high on another spike in revenue, again upping its full-year expectations after increasing profits by more than 50%.